Boston Scientific’s Eluvia Drug-Eluting Vascular Stent Compared to BMS at 1 Year in EMINENT Study

October 6, 2021—Boston Scientific announced the presentation of data for the Eluvia drug-eluting vascular stent system, which included 1-year results from the EMINENT trial that demonstrated superiority of the Eluvia stent compared to self-expanding bare metal stents (BMS) for the treatment of patients with peripheral artery disease and superficial femoral artery (SFA) or popliteal artery (PPA) lesions up to 210 mm in length.

Professor Yann Gouëffic, MD, who is with the Department of Vascular and Endovascular Surgery at Paris Saint-Joseph Hospital in Paris, France, serves as Principal Investigator of the EMINENT study. Prof. Gouëffic presented the study’s 1-year findings during a late-breaking clinical trials session at the VIVA 2021, the annual Vascular InterVentional Advances meeting held October 4-7 in Las Vegas, Nevada.

According to Boston Scientific, the Eluvia drug-eluting vascular stent compared to BMS demonstrated the following in the 775-patient EMINENT study at 1 year:

• Superiority in primary patency rate (Kaplan-Meier estimate, 85.4% vs 76.3%; P = .0087).
• Significantly greater rate of sustained clinical improvement without reintervention, (83% vs 76.6%; P = .045).
• No significant difference in major adverse events or all-cause mortality rates.

“I am honored to have been part of this global study, which adds to the robust body of evidence from the IMPERIAL trial and confirms that the Eluvia stent should be considered the stent of choice for treating SFA and PPA lesions of intermediate length,” commented Prof. Gouëffic in the company’s press release. “The superior primary patency rates and greater rates of clinical improvement without reintervention are reassuring for physicians looking to make clinically based treatment decisions for their patients and reduce the need for repeat procedures.”